Laden…
[(7S)-6-(5-chloro-2-pyridinyl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate
Eszopiclone is a hypnotic sedative from the cyclopyrrolone group, primarily used for the treatment of sleep disorders. It acts as a positive allosteric modulator at the GABA-A receptor, thereby enhancing the inhibitory effect of GABA in the central nervous system. The substance has a relatively short duration of action and is often used to improve sleep onset and maintenance. Adverse effects may include drowsiness and cognitive impairments. The risk for dependence and withdrawal symptoms is moderate.
Class
Cyclopyrrolone
Pharmacological context
Mechanism
Eszopiclon ist das aktive S-Enantiomer von Racemzopiclon (Zopiclon) und...
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Receptor Targets
Mechanism of Action
Designations
IUPAC: 4-methylpiperazine-1-carboxylic acid [(7S)-6-(5-chloro-2-pyridyl)-5-keto-7H-pyrrolo[3,4-b]pyrazin-7-yl] ester
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Synapedia Evidence
Effects & Pharmacology is partially translated. Some details are still being expanded.
Eszopiclon ist das aktive S-Enantiomer von Racemzopiclon (Zopiclon) und positiv-allosterischer Modulator an GABAA-Rezeptoren an der Benzodiazepinbindungsstelle. Der pharmakologische mechanism of action ist mit Zopiclon identisch, jedoch mit ca. 2× höherer Potenz auf mg-Basis (da Racemzopiclon zur Hälfte aus dem inaktiveren R-Enantiomer besteht). Leichte α1-Subtypen-Bevorzugung (Sedierung, Amnesie) gegenüber α2/α3 (Anxiolyse). Längere Halbwertszeit als Zopiclon (6h vs 5h) und direkterer Metabolisierungsweg. CYP3A4-Substrat. Klinisch wichtig: Eszopiclon hat mit 6mg die höchste FDA-Dosierungszulassung unter Z-Hypnotika, was das Missbrauchs- und Abhängigkeitspotential verstärkt. Eszopiclon verursacht häufig einen persistierenden Dysgeusie (schlechten Nachgeschmack) — häufigster Grund für Therapieabbruch.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Reported range 2–3 mg
Total duration 6–8 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 1 mg |
| Reported | 2–3 mg |
| Strong | 5 mg |
Oral
Onset
30 minutes
Peak
1–2 hours
Total duration
6–8 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.